Curadigm is a nanotechnology company committed to improving treatment outcomes for millions of patients by redefining the therapeutic balance between bioavailability, toxicity, and efficacy. Curadigm is a Nanobiotix spin-off, incorporated in 2019, and based on a proprietary platform that aims to reshape and elevate the efficacy of intravenously administered therapeutics. Curadigm’s technology is focused on engineered biocompatible nanoparticles that transiently occupy the pathways responsible for therapeutic clearance and hepatic toxicity. This leads to enhanced systemic bioavailability, and improved accumulation in the target tissues. This augments the beneficial aspects of therapeutics while mitigating toxicities to increase patient quality of life, improve outcomes, and decrease costs. Curadigm’s technology is widely applicable and can be adapted to work with multiple therapeutic classes, including nanomedicines, nucleic acid therapeutics, small molecules, and gene editing technologies across multiple therapeutic areas. The broad utility of the company’s technology combined with its transformational nature signal significant market potential. Development will include multiple partnerships to rapidly advance programs into the clinic, drive early company revenue, and diversify risk.